Skip to content
Peptigraph home

VANQUISH 1: VK2735 Phase 3 trial (NCT07104500)

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

Registry record checked

At a glance

Phase
Phase 3
Status
Active, not recruiting
Enrolment
4,500
estimated
Start
23 Jun 2025 (actual)
Primary completion
1 Jul 2027 (estimated)
Sponsor
Viking Therapeutics, Inc.
Design

Arms and doses

NCT07104500 study arms
ArmTypeInterventionsDescription
Placebo AssignmentPlacebo comparatorDrug: VK2735VK2735 Placebo Comparator Once Weekly
Active Assignment (Dose 1)ExperimentalDrug: VK2735VK2735 7.5mg Once Weekly
Active Assignment (Dose 2)ExperimentalDrug: VK2735VK2735 12.5mg Once Weekly
Active Assignment (Dose 3)ExperimentalDrug: VK2735VK2735 17.5mg Once Weekly
Endpoints

Primary endpoint

NCT07104500 primary outcomes
MeasureTime frame
Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment78 Weeks
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT07104500 secondary outcomes
MeasureTime frame
Percentage of participants who achieve ≥5%, ≥10%, ≥15% and ≥20% body weight reduction after 78 weeks of treatment78 Weeks
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
Not stated
Results

Results

No results posted on ClinicalTrials.gov as of 2 Oct 2026.

Sources

  1. 1A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid ConditionClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026

Found an error? Report a correction.